Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 1× · first seen 10-sep-2026 · last seen 10-sep-2026

TWEAK/Fn14 Targeting

Current understanding

To be populated as evidence accumulates.

Evidence log

  • 2026-08-14 — Targeting TWEAK to enhance mitochondrial biogenesis and attenuate age-related muscle mass loss.: Aged-mouse AAV9 TWEAK knockdown (injections at 15 and 17 months, readout at 18 months) plus lentiviral silencing in DEX-treated C2C12 myotubes raised SIRT1/PGC-1α/p-AMPK, lowered mitochondrial ROS and inflammatory cytokines via p38 MAPK suppression, and attenuated age-related muscle mass loss — but forelimb grip strength did not significantly improve. [animal-model] (novelty: 3)

Open questions

Related

Contributing findings

pubmed preclinical animal-model
Targeting TWEAK to enhance mitochondrial biogenesis and attenuate age-related muscle mass loss.
14-aug-2026 novelty 3 per-area 3 strengthens

build build 880 · 2bcef25 · 2026-11-18